Last reviewed · How we verify
Allerslit forte
Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses.
Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses. Used for Allergic rhinitis and/or allergic asthma caused by specific environmental allergens.
At a glance
| Generic name | Allerslit forte |
|---|---|
| Sponsor | Allergopharma GmbH & Co. KG |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This is an allergenic extract-based immunotherapy designed to modulate immune tolerance to environmental allergens. By administering progressively higher concentrations of allergen extract, the treatment aims to shift the immune response from IgE-mediated hypersensitivity toward IgG-mediated tolerance and regulatory T cell activation, thereby reducing allergic symptoms upon natural allergen exposure.
Approved indications
- Allergic rhinitis and/or allergic asthma caused by specific environmental allergens
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Anaphylaxis
Key clinical trials
- Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children (PHASE3)
- Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |